Sat, Aug 30, 2014, 12:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

mauricethepantsman 75 posts  |  Last Activity: 21 hours ago Member since: Feb 9, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • at ASCO 2014 Annual Meeting. This is just the beginning of the rise in share price for SNSS. News like this will be the catalyst for the pps to rise before the unveiling of the Phase III results of Qinprezo.

    Let the shorts get their pants lit up on this news!

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Aside from all the BS Spam on this board....

    by mrdtino Jun 4, 2014 11:36 AM
    mauricethepantsman mauricethepantsman Jun 4, 2014 6:13 PM Flag

    Well put! I'm biding my time. I've owned this stock since 2010. What's a few more months?

    Payday is around the corner friend.

    GLTAL

    Sentiment: Strong Buy

  • This timing would be perfect. Is this a possibility? You bet it is. Roche would jump all over INO if the Phase II results are announced as positive. 300% increase in pps is not out of the question.

    Sentiment: Strong Buy

  • Here we go! Up $1.35 in premarket this morning.

    Received email from Inovio announcing the initiation of the trial.

    GLTAL!

    Sentiment: Strong Buy

  • mauricethepantsman mauricethepantsman Jun 10, 2014 7:36 AM Flag

    Correction on pps in premarket. $ .42 cents not $1.35. Reset of pps from close didn't occur when I first posted. Sorry friends!

    Sentiment: Strong Buy

  • This stock will see big volume and a good increase in pps during regular trading. Let's not forget the inclusion into the Russell 2000 this Friday. Huge!

    GLTAL!

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 3:58 PM Flag

    We will be vindicated when they announce the findings and he will turn into a T U R D !

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 4:09 PM Flag

    Forget about Alan and his hit piece.
    We will be vindicated when they announce the findings and he will turn into a jaded liar!

  • Reply to

    I didn't sell

    by cameron12x Jun 10, 2014 4:14 PM
    mauricethepantsman mauricethepantsman Jun 10, 2014 4:24 PM Flag

    Neither did I. I would rather wait for the results than to believe some "analyst" from the Street! What a pity! I feel sorry for AF because he is "mindless".

    GLTAL!

    Sentiment: Strong Buy

  • Let's flood AF with tweets and emails calling out his stupidity on his call today! He deserves at least to be called out!

    Sentiment: Strong Buy

  • Let's be realistic. In the same article that AF is spewing falsehoods about, Dr. Kim was asked if he had sold any shares of the stock. His answer was a firm "NO".

    Seriously, does this seem a little strange to you if he had information regarding the drug failing. He stands to lose MILLIONS of his own money.

    Sentiment: Strong Buy

  • This bantering back and forth is not making us any richer, nor is it doing any justice to the stock. INO is revolutionary in it's ability to fight cancer. Let's treat it with the respect that it is due. It will save millions of lives in the near future. We do not have to defend it!!!!

    INO will speak for itself soon enough! LET IT GO!!!!

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 7:36 PM Flag

    Here is the article AF wrote today at 12:23PM.

    Inovio CEO Preps Retail Investors for Drug Study Failure

    By: Adam Feuerstein | 06/10/14 - 12:23 PM EDT
    inShare

    Comment
    Link

    Inovio Pharmaceuticals (INO) CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?

    The red flags flying over Inovio are there for any clear-eyed investor to see:

    Inovio pushed through shareholder vote approving a 1-for-4 reverse stock split on May 23, which went into effect on June 5. Why the need for a reverse stock split? Kim explained:

    Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience.

    Interesting spin. Drug companies in leadership positions aren't generally valued with stock prices in the $2 range. More typically, terminally depressed stock prices -- like Inovio's -- are the direct result of management incompetence and/or drug development setbacks and failures. Innovio is very good at issuing press releases and promoting its stock to retail investors, but its track record of developing DNA vaccines is abysmal.

    Inovio's decision to enact a reverse stock split right before the VGX-3100 results was more likely timed purposefully to keep the stock trading above $1 if the study fails. Well played, Kim!

    Kim hints at negative VGX-3100 study results in Monday's interview conducted by a Seeking Alpha contributor.

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 7:45 PM Flag

    In the interview, Seeking Alpha contributor Trevor Lowenthal asks Kim, "Inovio is expected to produce a top line data read-out for its experimental HPV immunotherapy, VGX-3100, very shortly. How crucial is this to Inovio's future?"

    Kim's response:

    The upcoming data will help define the potential clinical utility of this HPV immunotherapy for late-stage cervical pre-cancers. But the efficacy and immune response data together are going to help define the broad potential of the products based on our expansive DNA immunotherapy and electroporation technologies as monotherapies and as combinations with complementary technologies, such as checkpoint inhibitors. [Emphasis added.]

    Later in the interview, Kim is asked, "What are the primary risks facing the company?"

    Again, Kim's response:

    If you are defining risk as what might negatively impact the company's market valuation, I think the obvious risk is that our upcoming Phase II efficacy data does not meet our primary goal and the market looks at the data simplistically and says INO is a sell. However, smart investors are going to be looking closely at our T cell data and making investment decisions with that as well. We have tremendous confidence that we can ultimately see clinical utility of one of our products as a monotherapy, either with one of our immunotherapies by itself or possibly with an immune activator included. But cancer is complex, and it may very well be the case that different mechanisms need to be used in conjunction to achieve the desired impact against cancer. [Emphasis added.]

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 7:55 PM Flag

    The study's primary endpoint is a comparison of the number of patients with regression of CIN to grade 1 or less at nine months.

    Based on the medical literature, you can expect approximately 35% of the women in the placebo arm of study to have complete regression of their CIN 2/3 cervical lesions. Keep that in mind when Inovio reports results from the VGX-3100 study. I suspect Kim knows his vaccine is in trouble, hence his need to prime retail investors with the "T-cell response" bamboozle.

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 10, 2014 7:57 PM Flag

    Let's unpack Kim's statement. If treatment with VGX-3100 fails to shrink high-grade pre-cancerous cervical lesions more than a placebo (the study's primary endpoint), it would be "simplistic" to consider the vaccine a failure and sell Inovio. Instead, "smart investors" will disregard the miss on the study's primary efficacy endpoint and reward Inovio if VGX-3100 causes a T-cell response in patients, even though T-cell response is not listed as an endpoint in the phase II study.

    Don't be fooled by Inovio's smoke and mirrors. A T-cell response to VGX-3100 absent a statistically significant shrinkage in cervical lesions compared to placebo is clinically meaningless. It's a failure.

    In a 2010 study published in the journal Cancer Immunology Immunotherapy which followed 50 women with high-grade cervical intraepithelial neoplasia (CIN 2/3) -- the same type of patients Inovio enrolled in the VGX-3100 phase II study -- Trimble et al found that systemic immune response (a T-cell response) did not predict regression of CIN 2/3 lesions.

    Moreover, 26% of the CIN 2/3 lesions followed in the Trimble study shrank completely on their own, without any treatment, after 15 weeks. You can find other studies in the medical literature which cite CIN 2/3 complete regression rates of approximately 35%.

    In other words, the efficacy bar for VGX-3100 is very high, which explains Kim's desire to walk back expectations.

    All the 148 women enrolled in the Inovio phase II study are confirmed positive for the human papillomavirus (HPV) serotypes 16 and 18, and have a baseline diagnosis of CIN grades 2 or 3, meaning they present with abnormal cells on their cervix which carry a moderate to higher risk for progressing to cancer.

    Women in the study are randomized into two groups. The first group receives injections of VGX-3100 followed by electroporation at months 0, 1 and 3. The second group receives a placebo injection followed by electroporation on the same time schedule.

    Sentiment: Strong Buy

  • mauricethepantsman by mauricethepantsman Jun 11, 2014 7:51 AM Flag

    Let's move on. Badgering each other is a waste of time and energy. We should act like civilized adults. Suck it up and and let's see what the day will bring. Nothing we say will change the what has occurred yesterday or today.

    GLTAL!

    Sentiment: Strong Buy

  • Reply to

    UBS out with a buy rating at $14.00....

    by mrdtino Jun 11, 2014 4:52 PM
    mauricethepantsman mauricethepantsman Jun 12, 2014 7:27 AM Flag

    I haven't seen anything on this at all! The Bid this morning is $5.80 an the ask is $6.00. Looks like a good day coming for SNSS. Hope something comes to print this morning on Yahoo Finance. WORLD NEEDS TO KNOW HOW GREAT THIS DRUG IS!

    GLTAL

    Sentiment: Strong Buy

  • Reply to

    Hey Maurice!

    by fuchujoe Jun 12, 2014 8:45 AM
    mauricethepantsman mauricethepantsman Jun 12, 2014 8:49 AM Flag

    Look for my email Joe!

    Sentiment: Strong Buy

  • Reply to

    russell 2000 additions

    by hydra_investor123 Jun 13, 2014 7:14 PM
    mauricethepantsman mauricethepantsman Jun 13, 2014 8:04 PM Flag

    Here is the URL for the 2014 Russell 2000 rebalancing/additions.

    http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page

    GLTAL!

    Sentiment: Strong Buy

SNSS
7.49-0.29(-3.73%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.